Genzyme Flanders

FlandersBio on Twitter

Biotech company Ablynx wins European Mediscience Award: http://tiny.cc/knen6

posted 1 month ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.genzyme.be
Email:
Phone: +32 14 56 49 11
FlandersBio Member
More address details

Business Focus

Genzyme is a global biopharmaceutical company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, immune-mediated disease, oncology and osteoarthritis, and includes an industry-leading array of diagnostic products and genetic services.

Company Profile

Genzyme's commitment to innovation continues today with research into novel approaches to genetic disease, cancer, heart disease, and other areas of unmet medical need. More than 12,000 Genzyme employees in offices around the globe, of which more than 2,700 in Europe, serve patients in over 80 countries.

Subsidiaries in Belgium:

Genzyme Belgium NV, founded in 1993, has offices in Brussels, holding Corporate Affairs Europe and Sales & Marketing Belgium (employees > 30).
Genzyme Flanders BVBA founded in 2001 located in Geel, a large manufacturing site for biopharmaceuticals (employees >350).

Science & Technology or Services

Genzyme has strong development programs using multiple technologies to investigate cancer, cardiovascular diseases, and immune diseases. In research and development, the company takes a pragmatic approach that gives freedom to apply diverse technologies to specific medical areas. These technologies include proteins, polymers, small molecules, biomaterials, cell therapy and gene therapy.

Product description

Lysosomal Storage Disorders:

Enzyme replacement treatment for Type 1 Gaucher disease.
Enzyme replacement treatment for Fabry disease.
Enzyme replacement treatment for Mucopolysaccharidosis I (MPS I).
Enzyme replacement treatment for Pompe disease.

Renal:

A unique calcium-free, metal-free phosphate binder indicated for the control of serum phosphorus in patients with Chronic Kidney Disease on hemodialysis.
A vitamin D2 analogue indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease Stages.

Orthopaedics:

A local therapy that provides lubrication for the knee joint and helps to reduce or to stop pain in an osteoarthritic knee.
Autologous cultured chondrocytes to help repair damaged knee cartilage in patients with injuries caused by acute or repetitive trauma.

Transplant:

An immunosuppressive polyclonal antibody that is used in conjunction with concomitant immunosuppression to treat acute rejection in transplant patients.

Oncology:

A humanized monoclonal antibody indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients.
A small molecule was granted marketing approval for the treatment of children with refractory or relapsed acute lymphoblastic leukemia (ALL). ALL is the most common form of pediatric leukemia
Recombinant human hormone as an adjunctive diagnostic used in follow-up screenings of cancer patients with well-differentiated thyroid cancer who have had their thyroid glands removed.

Alliances

Genzyme seeks strategic collaborations to expand its portfolio of commercialized products and services, to supplement its product pipeline, and to access complementary research, technology, and development capabilities. The company focuses on first-rate science and on opportunities that address well-defined patient populations with unmet or underserved medical need.

Some major partnerships: